Coombers G B, Hall R R, Laurence J R, Neville A M
Br J Cancer. 1975 Feb;31(2):135-42. doi: 10.1038/bjc.1975.18.
A total of 190 patients being treated or followed up for urothelial carcinoma have been studied by the serial estimation of their urinary and plasma CEA levels. Only 46% of patients with a urothelial neoplasm present have a raised urinary CEA level. Infection or ileal conduit urine vitiate the result as they produce high CEA levels in the urine in the absence of any neoplastic disease. The accuracy of urinary CEA estimations is compared with that of cytology. Plasma CEA levels do not serve as a useful guide to the presence of extra-urinary tract tumour spread if taken as isolated readings. However, serial plasma CEA estimations may indicate that metastatic disease is present several months before its detection by the more usual clinical methods in a minority of patients.
通过对190例接受尿路上皮癌治疗或随访的患者进行尿液和血浆癌胚抗原（CEA）水平的系列评估，对其进行了研究。在患有尿路上皮肿瘤的患者中，只有46%的患者尿液CEA水平升高。感染或回肠造口尿液会使结果无效，因为它们在没有任何肿瘤疾病的情况下会使尿液中的CEA水平升高。将尿液CEA评估的准确性与细胞学的准确性进行了比较。如果将血浆CEA水平作为单独读数，它并不能作为判断尿路外肿瘤扩散情况的有用指标。然而，在少数患者中，系列血浆CEA评估可能表明在通过更常规的临床方法检测到转移疾病前几个月就已存在转移疾病。
